gemcitabine has been researched along with gdc-0973 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bou-Reslan, H; Cao, T; Carano, R; Castillo, J; Chan, E; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, W; French, D; Hoeflich, KP; Junttila, MR; Merchant, M; Metcalfe, C; Nannini, MA; Otter, DD; Singh, M | 1 |
| Bouvet, M; Clary, BM; Delong, JC; Hoffman, RM; Hwang, HK; Igarashi, K; Kawaguchi, K; Kiyuna, T; Lwin, TM; Murakami, T; Unno, M | 1 |
2 other study(ies) available for gemcitabine and gdc-0973
| Article | Year |
|---|---|
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Indazoles; MAP Kinase Kinase 1; Mice; Models, Biological; Mutation; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Standard of Care; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX).
Topics: Animals; Antineoplastic Agents; Azetidines; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2017 |